Men’s Health and Testosterone Replacement Therapy: Symptoms, Treatments, and Peptides for Body Composition at C3 Contemporary Care Clinic

Men’s health often centers on energy, strength, libido, mood, and body composition. Testosterone plays a central role in all of these. When levels drop—whether from aging, obesity, metabolic issues, environmental exposures, or other medical conditions—many men experience noticeable declines that affect quality of life. At C3 Contemporary Care Clinic in Rockwall, Texas, we take a personalized, evidence-informed approach to evaluating low testosterone (hypogonadism), offering testosterone replacement therapy (TRT) options, discussing fertility preservation strategies, and reviewing adjunctive approaches including certain peptides that support body composition.

This guide covers common symptoms of low testosterone, the potential contribution of environmental endocrine disruptors, standard TRT approaches, fertility considerations, how peptides (both FDA-approved and non-FDA-approved options used in clinical or compounding contexts) may fit into body-composition goals, and the importance of medical supervision. Always consult a qualified provider for personalized evaluation—self-diagnosis or unsupervised use carries risks.

Symptoms of Low Testosterone in Men's Health

Low testosterone (male hypogonadism) symptoms can be gradual and overlap with other conditions such as sleep apnea, depression, thyroid issues, or obesity. Diagnosis typically requires both consistent symptoms and confirmatory morning blood tests (often two separate measurements of total testosterone, sometimes with free testosterone, LH, FSH, and other markers).

Common symptoms include:

•       Reduced sex drive (libido) and fewer spontaneous or morning erections

•       Erectile dysfunction or difficulty maintaining erections

•       Persistent fatigue or low energy that sleep does not fully resolve

•       Decreased muscle mass, strength, or endurance, and difficulty building muscle

•       Increased body fat, especially visceral (abdominal) fat

•       Mood changes: irritability, depressed mood, or reduced motivation

•       Difficulty concentrating, brain fog, or mild cognitive changes

•       Reduced body or facial hair growth; in some cases, smaller or softer testicles

•       Hot flashes or night sweats (less common)

•       Decreased bone density over time (raising fracture risk)

•       Gynecomastia (breast tissue growth) in some men

Sexual symptoms tend to be more specific to low testosterone, while fatigue and mood changes are less specific and require careful differential diagnosis.

Prevalence rises with age; levels typically decline about 1% per year after age 30, and conditions such as obesity, type 2 diabetes, and certain medications accelerate the drop. Untreated low testosterone can contribute to reduced quality of life, metabolic issues, and lower bone density.

Environmental Exposures and Endocrine Disruptors

Beyond aging, obesity, and medical conditions, a growing body of research links certain environmental chemicals—collectively called endocrine-disrupting chemicals (EDCs)—to adverse effects on male reproductive hormone balance, including lower testosterone levels and impaired spermatogenesis. These substances can interfere with hormone receptors, steroidogenic enzymes, the hypothalamic-pituitary-gonadal (HPG) axis, or induce oxidative stress in the testes.

Common categories of concern include:

•       Phthalates (plasticizers found in many consumer products, food packaging, and personal-care items). Metabolites such as DEHP-related compounds have been associated in epidemiological studies with lower total and free testosterone, particularly with higher exposures during adolescence.

•       Bisphenol A (BPA) and related analogs (found in some plastics, can linings, and thermal paper). These can act as weak estrogen-receptor agonists or androgen-receptor antagonists and have been linked in observational data to altered hormone profiles and reduced semen quality.

•       Pesticides and herbicides (including certain organophosphates and other agricultural chemicals). Occupational and environmental exposure has been associated with lower testosterone, changes in gonadotropins, and poorer sperm parameters in some studies.

•       Per- and polyfluoroalkyl substances (PFAS) (“forever chemicals”). Certain PFAS have shown inverse associations with testosterone in young men in multiple studies.

•       Heavy metals (such as cadmium and lead) and persistent organic pollutants (PCBs, certain flame retardants) can also disrupt steroidogenesis or act through oxidative and epigenetic pathways.

Critical windows of susceptibility include fetal development (the “masculinization programming window”) and puberty/adolescence, when the reproductive axis is particularly sensitive. Adult exposure may still contribute to lower circulating testosterone or reduced fertility potential, although effect sizes in population studies are often modest and influenced by cumulative mixture exposures.

Practical risk-reduction steps that patients can discuss with their clinician include minimizing unnecessary plastic food contact (especially when heating), choosing fragrance-free or phthalate-aware personal-care products when feasible, washing produce thoroughly, reducing occupational chemical exposure with appropriate protective measures, and supporting overall metabolic health (which itself influences hormone clearance and sensitivity). Routine clinical evaluation for low testosterone does not typically include specialized EDC biomonitoring; the emphasis remains on symptoms, confirmed laboratory values, and modifiable lifestyle and medical factors.

At C3, discussion of potential environmental contributors occurs in the broader context of comprehensive evaluation rather than as a primary diagnostic tool. Evidence continues to evolve, and individual attribution of low testosterone solely to environmental chemicals is rarely possible.

Testosterone Replacement Therapy (TRT) Options

TRT is indicated for men with confirmed low testosterone plus symptoms and an associated medical condition (or, under evolving clinical judgment and labeling discussions, certain age-related cases after careful evaluation). FDA-approved testosterone products are intended for men who lack or have low testosterone due to specific conditions; they are not approved solely for “anti-aging” in otherwise healthy men.

Available FDA-approved delivery methods include:

•       Injectable testosterone (cypionate, enanthate, or longer-acting undecanoate): Often weekly or biweekly intramuscular or subcutaneous injections. Cost-effective and flexible dosing; levels can fluctuate between doses.

•       Transdermal gels or solutions: Daily application to skin. Convenient but risk of transfer to others and variable absorption.

•       Patches: Daily skin application; can cause skin irritation.

•       Pellets: Implanted under the skin every 3–6 months for steady release.

•       Oral capsules (testosterone undecanoate formulations such as Jatenzo, Tlando, Kyzatrex): Absorbed via lymphatic system; convenient but may require multiple daily doses and monitoring of blood pressure.

•       Nasal gel or buccal systems: Less common; require frequent dosing.

Benefits of properly supervised TRT in appropriate candidates can include improved libido, energy, mood, muscle mass, and body composition (increased lean mass and reduced fat), along with support for bone density. Effects on sexual symptoms often appear sooner; body-composition and bone changes take longer (weeks to months).

Monitoring is essential: periodic labs (testosterone levels, hematocrit, PSA, lipids, estradiol as indicated), prostate health assessment, and evaluation for side effects such as elevated red blood cell count, acne, fluid retention, worsening sleep apnea, or potential prostate effects. TRT can suppress natural sperm production, so fertility goals must be discussed before starting therapy. Lifestyle foundations—resistance training, adequate protein, sleep, weight management, and treating underlying conditions—remain critical.

TRT and Fertility Preservation

Exogenous testosterone suppresses the HPG axis by providing negative feedback that lowers luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The resulting drop in intratesticular testosterone and reduced FSH support commonly impairs spermatogenesis. A substantial proportion of men on TRT develop oligospermia or azoospermia within months; recovery after discontinuation is possible but can take 6–24 months and is not guaranteed in every case.

Major guidelines (including AUA and Endocrine Society guidance) recommend against initiating exogenous testosterone in men who are actively trying to conceive and emphasize discussion of long-term fertility impact with any patient interested in future paternity. Several evidence-based strategies exist to protect or restore fertility potential:

Sperm Banking (Cryopreservation)

Banking sperm before starting TRT remains the only guaranteed insurance policy. A baseline semen analysis can also identify preexisting fertility issues. This option is especially valuable for men who may later desire biological children regardless of concurrent medical protocols.

Concurrent Low-Dose hCG with TRT

Human chorionic gonadotropin (hCG) mimics LH and stimulates Leydig cells to maintain intratesticular testosterone production even while pituitary LH is suppressed. Typical fertility-preservation dosing is in the range of 250–500 IU subcutaneously two to three times weekly (or every other day), individualized by response and monitoring. Studies have shown that concurrent low-dose hCG can substantially preserve sperm production and prevent the profound drop in intratesticular testosterone seen with TRT alone. This is the most commonly used concurrent strategy in fertility-aware clinics.

Selective Estrogen Receptor Modulators (SERMs)

Clomiphene citrate (and the purified isomer enclomiphene in compounded settings) block estrogen feedback at the hypothalamus/pituitary, raising endogenous LH and FSH. This can increase the body’s own testosterone production while generally preserving spermatogenesis. SERMs are often considered for men with secondary (central) hypogonadism who prioritize fertility, either as monotherapy instead of TRT or as part of a recovery protocol. Monitoring of LH, testosterone, and estradiol is required. Enclomiphene is not FDA-approved as a commercial product for this indication and is used in compounded form under appropriate medical supervision.

Aromatase Inhibitors and Combination Approaches

In selected cases, aromatase inhibitors (e.g., anastrozole) may be used to optimize the testosterone-to-estradiol ratio. For men already suppressed by prior TRT or anabolic steroid use who wish to restore fertility, higher-dose hCG (sometimes with recombinant FSH) and/or SERMs are employed in stepwise recovery protocols. Response rates vary; not every man regains normal parameters.

Key clinical principles at C3: Fertility goals are discussed before any TRT is started. When future or current paternity is a priority, alternatives that stimulate endogenous production (SERMs, hCG monotherapy) or concurrent hCG with TRT are preferred over TRT alone. Semen analysis, serial hormone monitoring, and individualized dosing are essential. These approaches are off-label for fertility preservation in many cases and require a knowledgeable clinician, ongoing laboratory follow-up, and realistic counseling about success rates and timelines.

Men who have already started TRT and later wish to conceive should not stop therapy abruptly without medical guidance; a structured recovery plan is safer and more effective.

Peptides for Body Composition: FDA-Approved and Non-FDA-Approved Options

Body composition (fat loss with lean-mass preservation or gain) is a frequent goal alongside TRT. Certain peptide-based therapies influence growth hormone (GH)/IGF-1 axis activity or metabolic pathways that affect fat distribution and muscle. Regulatory status varies widely: some are fully FDA-approved for specific indications; others are compounded under Section 503A rules (patient-specific prescriptions) or exist in more restricted/research contexts. Availability, legality, and evidence quality differ, and none of the non-approved options should be viewed as substitutes for TRT when true hypogonadism is present.

FDA-approved options with body-composition relevance:

•       Tesamorelin (Egrifta / Egrifta SV): A growth hormone-releasing hormone (GHRH) analog FDA-approved specifically for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Clinical trials showed significant reductions in visceral adipose tissue. It is not approved for general weight loss or non-HIV body recomposition; any broader use is off-label. Effects on muscle density have been observed in secondary analyses. Long-term cardiovascular safety data beyond the approved indication are limited.

•       GLP-1 receptor agonists (and dual agonists) such as semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro): These are peptide-based medications FDA-approved for chronic weight management (and diabetes). They produce substantial fat loss (often 15%+ body weight with tirzepatide in trials) with relative preservation of lean mass when combined with resistance training and protein intake. Emerging data show they can raise total and free testosterone in men with obesity-related hypogonadism, sometimes independently of weight loss alone, and may improve metabolic health and fertility markers compared with TRT in select obese men. Muscle loss can still occur without exercise; combining with strength training is recommended.

Non-FDA-approved or previously approved/compounded options sometimes discussed for body composition or GH support:

•       Sermorelin: A GHRH analog previously FDA-approved for diagnostic or pediatric GH deficiency uses (commercial product withdrawn for business reasons). Compounded versions are used off-label to stimulate pulsatile GH release. Evidence for adult body-composition benefits is limited compared with approved agents.

•       CJC-1295 (with or without DAC) + Ipamorelin: GHRH analog and ghrelin mimetic combinations that stimulate GH release. Not FDA-approved; compounding status has faced FDA scrutiny and restrictions in recent years. Human data on body composition are modest; primarily pharmacokinetic and limited observational.

•       Other research or compounded peptides (e.g., certain GHRPs, BPC-157, TB-500, AOD-9604, MOTS-c): Lack robust Phase 3 human data for body composition or testosterone support. Many sit in restricted compounding categories or research-chemical markets. Safety, purity, and long-term effects are less established. Regulatory status continues to evolve.

Important caveats: GH secretagogues primarily affect the GH/IGF-1 axis rather than directly raising testosterone. They may complement TRT for recovery, sleep, or visceral fat in select patients under medical supervision, but they are not TRT alternatives. Fertility-preserving approaches (e.g., hCG or certain SERMs in appropriate cases) exist separately. All peptide use requires prescription, monitoring (including IGF-1), and discussion of risks (glucose effects, potential fluid retention, injection-site issues, unknown long-term safety for unapproved uses). Sourcing from unregulated online vendors is unsafe.

At C3 Contemporary Care Clinic we emphasize evidence-based, supervised care. Hormone optimization, weight-management strategies (including appropriate GLP-1 therapies when indicated), fertility planning, and discussion of adjunctive options occur in the context of comprehensive evaluation, labs, and lifestyle support via telehealth as appropriate.

Putting It Together: A Practical Approach

1.     Recognize symptoms and seek evaluation rather than self-treating.

2.     Confirm low testosterone with proper labs and clinical assessment; consider contributing factors such as obesity, sleep, medications, and potential environmental exposures.

3.     Address root contributors (weight, sleep, medications, metabolic health, and practical steps to reduce unnecessary chemical exposures).

4.     Discuss fertility goals explicitly before starting any testosterone therapy. Consider sperm banking, concurrent hCG, or SERM-based approaches when preservation is desired.

5.     Consider TRT when indicated, choosing a delivery method that fits lifestyle and medical profile.

6.     Discuss body-composition goals—resistance training + protein is foundational; FDA-approved agents such as tesamorelin (for its specific indication) or GLP-1 medications (for weight management) have the strongest evidence; other peptides require careful risk-benefit discussion.

7.     Commit to ongoing monitoring and follow-up.

Men’s health is multifactorial. Optimizing testosterone when deficient, protecting fertility when it matters, supporting favorable body composition, reducing avoidable environmental burdens where practical, and maintaining metabolic health can meaningfully improve energy, strength, sexual function, and overall well-being. Results vary; realistic expectations and medical partnership matter most.

Ready to take the next step? Contact C3 Contemporary Care Clinic to schedule a consultation. We offer personalized hormone therapy, fertility-aware protocols, weight-management support, and discussion of peptide options under medical supervision, with a focus on transparent, patient-centered care.

References

• Mayo Clinic. Male hypogonadism – Symptoms & causes; Low testosterone overview.

• Cleveland Clinic. Low Testosterone (Low T): Hypogonadism, Symptoms & Treatment; Testosterone Replacement Therapy.

• Endocrine Society Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism; AUA Evaluation and Management of Testosterone Deficiency Guideline (including fertility-related recommendations).

• FDA information on testosterone products, labeling updates, and approved formulations (including oral undecanoate products).

• Clinical data on concurrent hCG with exogenous testosterone for preservation of intratesticular testosterone and spermatogenesis; reviews of SERMs (clomiphene/enclomiphene) and recovery protocols.

• Clinical trial data and prescribing information for tesamorelin (Egrifta) – visceral fat reduction in HIV lipodystrophy.

• STEP, SURMOUNT, and related trials for semaglutide and tirzepatide body-composition and metabolic outcomes; emerging data on testosterone effects in men.

• Peer-reviewed literature on endocrine-disrupting chemicals (phthalates, BPA, pesticides, PFAS, heavy metals) and associations with male testosterone levels, semen quality, and reproductive development (including epidemiological and mechanistic studies).

• Peer-reviewed reviews and observational data on GH secretagogues, compounding status, and men’s health applications (various sources including NEJM, endocrine literature).

• Additional clinical resources on TRT delivery methods, monitoring, risks, and fertility preservation strategies.

This content is for educational purposes and does not constitute medical advice. Individual evaluation by a licensed healthcare provider is required before starting any hormone, fertility-preservation, or peptide therapy. Regulatory status of compounded peptides and certain fertility agents can change; verify current FDA guidance. Environmental exposure reduction is supportive and does not replace proper diagnosis and treatment of hypogonadism.